ArticleToxins2019
Phylogeny-Guided Selection of Priority Groups for Venom Bioprospecting: Harvesting Toxin Sequences in Tarantulas as a Case Study.
Article in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Comparative venomics suggests an evolutionary adaption of spider venom from predation to defense.Communications biology · 2025Article
- Venom Ex Machina? Exploring the Potential of Cell-Free Protein Production for Venom Biodiscovery.International journal of molecular sciences · 2024Article
- Determining the pharmacological potential and biological role of linear pseudoscorpion toxins via functional profiling.iScience · 2024Article
- Phylogenomics resolves long-standing questions about the affinities of an endangered Corsican endemic fly.Journal of insect science (Online) · 2024Article
- Article
- Article
- Venom biotechnology: casting light on nature's deadliest weapons using synthetic biology.Frontiers in bioengineering and biotechnology · 2023Review
- Article
- Review
- Profiling hymenopteran venom toxins: Protein families, structural landscape, biological activities, and pharmacological benefits.Toxicon: X · 2022Article
- Venomics of the Central European Myrmicine AntsToxins · 2022Article
- Modern venomics-Current insights, novel methods, and future perspectives in biological and applied animal venom research.GigaScience · 2022Article
- Antimicrobial, Insecticidal and Cytotoxic Activity of Linear Venom Peptides from the PseudoscorpionToxins · 2022Article
- A Spider Toxin Exemplifies the Promises and Pitfalls of Cell-Free Protein Production for Venom Biodiscovery.Toxins · 2021Article
- Article
- Morphological Analysis Reveals a Compartmentalized Duct in the Venom Apparatus of the Wasp Spider (Toxins · 2021Article
- Article
- An Economic Dilemma Between Molecular Weapon Systems May Explain an Arachno-atypical Venom in Wasp Spiders (Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal venoms are promising sources of novel drug leads, but their translational potential is hampered by the low success rate of earlier biodiscovery programs, in part reflecting the narrow selection of targets for investigation. To increase the number of lead candidates, here we discuss a phylogeny-guided approach for the rational selection of venomous taxa, using tarantulas (family Theraphosidae) as a case study. We found that previous biodiscovery programs have prioritized the three subfamilies Ornithoctoninae, Selenocosmiinae, and Theraphosinae, which provide almost all of the toxin sequences currently available in public databases. The remaining subfamilies are poorly represented, if at all. These overlooked subfamilies include several that form entire clades of the theraphosid life tree, such as the subfamilies Eumenophorinae, Harpactirinae, and Stromatopelminae, indicating that biodiversity space has not been covered effectively for venom biodiscovery in Theraphosidae. Focusing on these underrepresented taxa will increase the likelihood that promising candidates with novel structures and mechanisms of action can be identified in future bioprospecting programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.